+98.9%
OKLO vs MRNA
-9.6%
+108.5%
-89.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.8% | -2.2% | -2.6% | -4.6% |
| 7D | -17.0% | -12.7% | -4.3% | -16.0% |
| 30D | -28.4% | -20.7% | -7.7% | -26.9% |
| 3M | -52.4% | +46.3% | -98.6% | -54.0% |
| 6M | -68.3% | +305.2% | -373.5% | -74.1% |
| YTD | -72.3% | +561.2% | -633.6% | -78.7% |
| 1Y | -77.4% | +772.1% | -849.5% | -83.2% |
| 3Y | +92.3% | +147.0% | -54.6% | +56.1% |
| 5Y | +100.7% | -26.1% | +126.8% | +63.1% |
| All | +98.9% | -9.6% | +108.5% | +64.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling